Navigation Links
New marker of drug response may speed pace of lung cancer prevention trials
Date:1/8/2013

Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting 5, 10 or 15 years to discover which of them develop cancer and which, if any, experience survival benefit from the treatment. A University of Colorado Cancer Center study recently published in the journal Cancer Prevention Research proposes a possible waypoint on the way to benefit, which if validated, could dramatically reduce the number of patients needed and time required to test drugs for lung cancer prevention.

"Chemoprevention is an important approach that has been way behind in terms of scientific advances for lung cancer," says Fred R. Hirsch, MD, PhD, investigator at the CU Cancer Center and professor of medical oncology and pathology at the CU School of Medicine. "If we could find a surrogate endpoint for lung cancer mortality an intermediate endpoint it would make it much easier to conduct smaller trials in much shorter time."

The original intent of the study was to discover certain microRNAs whose level of expression might predict patients likely to respond to the possible chemopreventive drug, Iloprost. If an especially high or low microRNA expression predicted response, it would allow researchers to test the drug only in the population most likely to benefit. Unfortunately, while levels of seven miRNAs were found to be correlated with the appearance of lung cancer, none predicted response to the drug.

It might have been a dead-end study if it weren't for microRNA-34c.

To a striking degree, changes in the expression of this molecule six months after treatment correlated with benefit from the drug seen much later. In those who later showed benefit, microRNA-34c expression was down six months after treatment; in patients who showed no benefit, microRNA-34c expression remained unchanged.

"Instead of waiting for an endpoint 15 years in the future, we could potentially discover the effectiveness of chemopreventive agents only six months after treatment. It would speed up the pace of discovery and eventually bring new chemopreventive agents much faster to the market," Hirsch says.

Hirsch cautions that his discovery, with CU Cancer Center colleagues including Celine Mascaux, MD, PhD, of this potential intermediate endpoint is just that: potential. Further work is needed to validate the predictive power of miRNA-34c in showing chemopreventive response. But Hirsch and colleagues are hopeful not only that miRNA-34c could be this predictive waypoint, but that the cutting edge technique of looking beneath genes, beneath even RNA and mRNA into the molecular world of microRNA will help them discover the roots of the disease.

"The approach is new and it needs to be further explored," Hirsch says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Is the detection of early markers of Epstein Barr virus of diagnostic value?
2. BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research
3. U of M researchers: Newly discovered genetic markers could signal colon cancer development
4. Molecular and protein markers discovered for liver transplant failure from hepatitis C
5. Color-coded markers may help doctors diagnose neural diseases through the eyes
6. New biomarker for common lung cancer predicts responses to chemotherapy
7. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
8. Researchers identify genetic markers to predict male fertility
9. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
10. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
11. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: